Progesterone receptors in endometrial cancer invasion and metastasis: Development of a mouse model

Steroids

Volumn 68, Issue 10-13, 2003, Pages 795-800

  Hanekamp, Eline E ^a   Gielen, Susanne C J P ^a   Van Oosterhoud, Susanna A ^a   Burger, Curt W ^a   Grootegoed, J Anton ^a   Huikeshoven, Frans J ^a   Blok, Leen J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

In vivo model; Ishikawa endometrial cancer cell line; Progesterone receptors; Steroids; Tumor cell invasion and metastasis

Indexed keywords

GESTAGEN; PROGESTERONE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER CELL; CANCER INVASION; CONFERENCE PAPER; ENDOMETRIUM CANCER; FEMALE; GENETIC TRANSFECTION; METASTASIS; MODEL; MOUSE; NONHUMAN; OVARIECTOMY; PERITONEAL CAVITY; POLYMERASE CHAIN REACTION;

ANIMALIA;

EID: 0347627646     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2003.08.002     Document Type: Conference Paper

References (30)

1. Martin L., Finn C.A., Trinder G. DNA synthesis in the endometrium of progesterone-treated mice. J. Endocrinol. 56(2):1973;303-307.
2. Dai D., Wolf D.M., Litman E.S., White M.J., Leslie K.K. Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. Cancer Res. 62(3):2002;881-886.
3. Ueda M., Fujii H., Yoshizawa K., Abe F., Ueki M. Effects of sex steroids and growth factors on migration and invasion of endometrial adenocarcinoma SNG-M cells in vitro. Jpn. J. Cancer Res. 87(5):1996;524-533.
4. Fujimoto J., Ichigo S., Hori M., Morishita S., Tamaya T. Progestins and danazol effect on cell-to-cell adhesion and E-cadherin and alpha- and beta-catenin mRNA expressions. J. Steroid Biochem. Mol. Biol. 57(5/6):1996;275-282.
5. Dai D., Kumar N.S., Wolf D.M., Leslie K.K. Molecular tools to reestablish progestin control of endometrial cancer cell proliferation. Am. J. Obstet. Gynecol. 184(5):2001;790-797.
6. Hanekamp E.E., Kuhne E.C., Smid-Koopman E., de Ruiter P.E., Chadha-Ajwani S., Brinkmann A.O.et al. Loss of progesterone receptor may lead to an invasive phenotype in human endometrial cancer. Eur. J. Cancer. 38(Suppl. 6):2002;71-72.
7. Giangrande P.H., Pollio G., McDonnell D.P. Mapping and characterization of the functional domains responsible for the differential activity of the A and B isoforms of the human progesterone receptor. J. Biol. Chem. 272(52):1997;32889-32900.
8. Vegeto E., Shahbaz M.M., Wen D.X., Goldman M.E., O'Malley B.W., McDonnell D.P. Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol. Endocrinol. 7(10):1993;1244-1255.
9. Giangrande P.H., Kimbrel E.A., Edwards D.P., McDonnell D.P. The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. Mol. Cell. Biol. 20(9):2000;3102-3115.
10. Mote P.A., Balleine R.L., McGowan E.M., Clarke C.L. Colocalization of progesterone receptors A and B by dual immunofluorescent histochemistry in human endometrium during the menstrual cycle. J. Clin. Endocrinol. Metab. 84(8):1999;2963-2971.
11. Moutsatsou P., Sekeris C.E. Estrogen and progesterone receptors in the endometrium. Ann. N.Y. Acad. Sci. 816:1997;99-115.
12. Mote P.A., Balleine R.L., McGowan E.M., Clarke C.L. Heterogeneity of progesterone receptors A and B expression in human endometrial glands and stroma. Hum. Reprod. 15(Suppl. 3):2000;48-56.
13. Kumar N.S., Richer J., Owen G., Litman E., Horwitz K.B., Leslie K.K. Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: implications for unopposed estrogen action. Cancer Res. 58(9):1998;1860-1865.
14. Sakamoto H., Kinoshita K., Nakayama Y., Takami T., Ohtani K., Izuka S.et al. Gene expression in primary, metastatic and recurrent lesions of endometrial cancer. Gynecol. Obstet. Invest. 48(3):1999;215-220.
15. Fukuda K., Mori M., Uchiyama M., Iwai K., Iwasaka T., Sugimori H. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Gynecol. Oncol. 69(3):1998;220-225.
16. Fujimoto J., Ichigo S., Hori M., Nishigaki M., Tamaya T. Expression of progesterone receptor form A and B mRNAs in gynecologic malignant tumors. Tumour Biol. 16(4):1995;254-260.
17. Fujimoto J., Ichigo S., Hirose R., Sakaguchi H., Tamaya T. Clinical implication of expression of progesterone receptor form A and B mRNAs in secondary spreading of gynecologic cancers. J. Steroid Biochem. Mol. Biol. 62(5/6):1997;449-454.
18. Arnett-Mansfield R.L., deFazio A., Wain G.V., Jaworski R.C., Byth K., Mote P.A.et al. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res. 61(11):2001;4576-4582.
19. Sasaki M., Dharia A., Oh B.R., Tanaka Y., Fujimoto S., Dahiya R. Progesterone receptor B gene inactivation and CpG hypermethylation in human uterine endometrial cancer. Cancer Res. 61(1):2001;97-102.
20. Misao R., Nakanishi Y., Sun W., Iwagaki S., Fujimoto J., Tamaya T. Identification of exon-deleted progesterone receptor mRNAs in human uterine endometrial cancers. Oncology. 58(1):2000;60-65.
21. De Vivo I., Huggins G.S., Hankinson S.E., Lescault P.J., Boezen M., Colditz G.A.et al. A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc. Natl. Acad. Sci. U.S.A. 99(19):2002;12263-12268.
22. Lam W.C., Delikatny E.J., Orr F.W., Wass J., Varani J., Ward P.A. The chemotactic response of tumor cells: a model for cancer metastasis. Am. J. Pathol. 104(1):1981;69-76.
23. Smid-Koopman E, Blok LJ, Kuhne ECM, Burger CW, Helmerhorst TJM, Brinkmann AO, et al. Distinct functional differences of human progesterone receptors A and B on gene expression and growth regulation in two endomtrial carcinoma cell lines. J Society Gynecol Invest 2003;10(1):49-57.
24. Blok LJDRP, Kuhne ECM, Hanekamp EE, Grootegoed JA, Smid-Koopman E, Gielen SCJP, et al. Progestagenic effects of tibolone on human endometrial cancer cells. J Clin Endocrinol Metab 2003;88(5):2327-34.
25. Jordan V.C., Gottardis M.M., Robinson S.P., Friedl A. Immune-deficient animals to study "hormone-dependent" breast and endometrial cancer. J. Steroid Biochem. 34(1/6):1989;169-176.
26. Dardes R.C., O'Regan R.M., Gajdos C., Robinson S.P., Bentrem D., De Los Reyes A.et al. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo. Clin. Cancer Res. 8(6):2002;1995-2001.
27. Greenberger L.M., Annable T., Collins K.I., Komm B.S., Lyttle C.R., Miller C.P.et al. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2- piperidin-1-yl-ethoxy)-benzyl]-1H-in dol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats. Clin. Cancer Res. 7(10):2001;3166-3177.
28. Legro R.S., Kunselman A.R., Miller S.A., Satyaswaroop P.G. Role of androgens in the growth of endometrial carcinoma: an in vivo animal model. Am. J. Obstet. Gynecol. 184(3):2001;303-308.
29. Horvath G, Ferno M, Baldetorp B, Johansson M, Growth interaction between different tumor populations in human endometrial adenocarcinoma growing in nude mice .In Vivo 1993;7(6A):511-7.
30. Huang P., Taghian A., Allam A., Freeman J., Duffy M., Suit H. The effect of whole-body irradiation of nude mice on the tumor transplantability and control probability of a human soft tissue sarcoma xenograft. Radiat. Res. 145(3):1996;337-342.